Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism

Current international guidelines recommend discontinuing anticoagulant therapy for unprovoked acute pulmonary embolism or deep vein thrombosis after the first 3 months of treatment only in patients considered at high risk of bleeding [1, 2]. The rationale for this recommendation is that unprovoked venous thromboembolism (VTE) is associated with high rates of recurrence after anticoagulant therapy quantified as up to 50% in the first 10 years [3]. It remains, however, unknown how the assessment of the bleeding risk in the individual patient should be performed given the lack of sufficiently validated risk assessment models or scores, as well as outcome trials that successfully applied those tools [4, 5]. VTE-BLEED predicts fatal and/or intracranial bleeding in patients with venous thromboembolism treated with long-term anticoagulants <http://ow.ly/3hqg30iXK5a> We thank the steering committees of the Hokusai-VTE study and the RE-COVER trials for being allowed to use the data.